| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney. Buthiazide inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubules. Its mode of action involves inhibiting the sodium-chloride symporter. The compound affects renal epithelial cells by altering ion transport and cellular metabolism.
|
|---|---|
| ln Vitro |
Buthiazide inhibits sodium reabsorption in the distal convoluted tubules of the kidneys, promoting the excretion of sodium and water, thereby reducing blood pressure and fluid retention. It works by inhibiting the sodium-chloride symporter. The compound affects renal epithelial cells by altering ion transport and cellular metabolism.
|
| ln Vivo |
In vivo, buthiazide is used as a thiazide diuretic to treat hypertension and edema associated with congestive heart failure, liver cirrhosis, and renal disorders. It reduces blood pressure and fluid retention by promoting the excretion of sodium and water. The compound is used in cardiovascular and renal research.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for buthiazide involve measuring its inhibition of the sodium-chloride symporter in renal epithelial cells. Cells expressing the symporter are treated with buthiazide, and sodium or chloride uptake is measured using fluorescent or radioactive tracers. The compound's ability to inhibit ion transport is assessed.
|
| Cell Assay |
In vitro cellular assays for buthiazide involve treating renal epithelial cells with the compound and measuring ion transport, cell volume, or cellular metabolism. Cells are treated with various concentrations of buthiazide, and sodium or chloride uptake is measured. The compound's effects on cell function and ion homeostasis are evaluated.
|
| Animal Protocol |
In vivo animal studies for buthiazide typically involve administration to hypertensive animal models to assess its diuretic and antihypertensive effects. Blood pressure, urine output, and electrolyte excretion are measured. Buthiazide reduces blood pressure and promotes sodium and water excretion.
|
| ADME/Pharmacokinetics |
Buthiazide has a molecular weight of 353.85 and a molecular formula of C11H16ClN3O4S2. It is a thiazide diuretic that is orally active. The compound is used in cardiovascular and renal research. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and elimination.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of buthiazide have established its safety profile for use as a diuretic and antihypertensive agent. The compound is generally well tolerated at therapeutic doses. Common adverse effects may include electrolyte imbalances, dehydration, and metabolic changes. The compound should be used under appropriate medical supervision.
|
| References | |
| Additional Infomation |
Butizide is a benzothiadiazine drug.
Buthiazide (Butizide) is a thiazide diuretic and a 3-isobutyl analog of hydrochlorothiazide used to treat hypertension and edema. It works by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, promoting the excretion of sodium and water. Buthiazide is used in cardiovascular and renal research to study electrolyte transport, renal function, and blood pressure regulation. |
| Molecular Formula |
C11H16CLN3O4S2
|
|---|---|
| Molecular Weight |
353.83
|
| Exact Mass |
353.027
|
| CAS # |
2043-38-1
|
| PubChem CID |
16274
|
| Appearance |
White to off-white solid
|
| Density |
1.433g/cm3
|
| Boiling Point |
562.7ºC at 760mmHg
|
| Melting Point |
214-217ºC
|
| Flash Point |
294.1ºC
|
| Vapour Pressure |
1.09E-12mmHg at 25°C
|
| Index of Refraction |
1.572
|
| LogP |
4.392
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(N)=O)Cl)C
|
| InChi Key |
HGBFRHCDYZJRAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17)
|
| Chemical Name |
6-chloro-3-(2-methylpropyl)-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
|
| Synonyms |
Butizidum S 3500SaltucinS-3500EunephranS3500 Butizide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~141.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8262 mL | 14.1311 mL | 28.2622 mL | |
| 5 mM | 0.5652 mL | 2.8262 mL | 5.6524 mL | |
| 10 mM | 0.2826 mL | 1.4131 mL | 2.8262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
